ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer
source: pixabay.com

ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer

In late February 2022, biopharmaceutical company Trascenta Holding Limited ("Trascenta") provided an update on its clinical program for TST001, a monoclonal antibody therapy designed for those with locally advanced or…

Continue Reading ICYMI: First Patient Dosed in TST001 Study for Biliary Tract Cancer